Amgen, Inc. announced the end of a Phase 3 drug study aimed at treating metastatic pancreatic cancer, the company said in a written statement.
Amgen ended the trial following the recommendation of an independent committee review of the study conducted by the Date Monitoring Committee. Based on a review of the trial at a pre-planned interim, DMC concluded that it was unlikely to demonstrate the desired endpoint.
"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We would like to thank the patients, caregivers and investigators for their participation and engagement in the study."
Phase 3 of the study had been going on for about a year, according to Christine Regan, director of media communications for Amgen.
There were no safety concerns raised in the DMC review of the study, the company said.
By Leah Gillis